Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1880]
News [4357]
Articles [416]
Editorials [10]
Conferences [108]
elearning [41]
Higher doses of fulvestrant suggest in ER breast cancer
Dr Gilberto Amorín – Brazilian Nacional Cancer Institute, Rio de Janeiro...
Higher doses of fulvestrant suggest in ER breast cancer ( Dr Gilberto Amorín – Brazilian Nacional Cancer Institute, Rio de Janeiro, Brazil )
28 Oct 2014
Promoting early detection of breast cancer in low and middle income countries
Prof Felicia Knaul - Director of Harvard Global Equity Initiative, Cambridge...
Promoting early detection of breast cancer in low and middle income countries ( Prof Felicia Knaul - Director of Harvard Global Equity Initiative, Cambridge, USA )
22 Oct 2014
ESMO 2014: News Roundup
ecancer News Team
ESMO 2014: News Roundup ( ecancer News Team )
16 Oct 2014
ESMO 2014 Editor's roundup
Prof Gordon McVie - ecancer and European Institute of Oncology, Milan, Italy
ESMO 2014 Editor's roundup ( Prof Gordon McVie - ecancer and European Institute of Oncology, Milan, Italy )
8 Oct 2014
ESMO Highlights: Breast cancer
Prof Giuseppe Curigliano - European Institute of Oncology, Milan, Italy
ESMO Highlights: Breast cancer ( Prof Giuseppe Curigliano - European Institute of Oncology, Milan, Italy )
2 Oct 2014
Combination of capecitabine and bevacizumab improves progression-free survival...
Dr Joseph Gligorov - Assistance Publique Hôpitaux de Paris, Paris, France
Combination of capecitabine and bevacizumab improves progression-free survival in metastatic breast cancer ( Dr Joseph Gligorov - Assistance Publique Hôpitaux de Paris, Paris, France )
2 Oct 2014
Pertuzumab adds 16 months survival benefit to trastuzumab plus chemotherapy for...
Dr Sandra Swain - Washington Cancer Institute, Washington, USA
Pertuzumab adds 16 months survival benefit to trastuzumab plus chemotherapy for HER2-positive metastatic breast cancer ( Dr Sandra Swain - Washington Cancer Institute, Washington, USA )
28 Sep 2014
Pertuzumab adds 16 months survival benefit to trastuzumab plus chemotherapy for...
Dr Sandra Swain - Washington Cancer Institute, Washington, USA
Pertuzumab adds 16 months survival benefit to trastuzumab plus chemotherapy for HER2-positive metastatic breast cancer ( Dr Sandra Swain - Washington Cancer Institute, Washington, USA )
28 Sep 2014
The evolving treatment landscape for HER2-positive metastatic breast cancer
Dr Hatem Azim - Institut Jules Bordet, Brussels, Belgium
The evolving treatment landscape for HER2-positive metastatic breast cancer ( Dr Hatem Azim - Institut Jules Bordet, Brussels, Belgium )
18 Sep 2014
Navigating current treatment options for HER2-positive MBC: Patient journey 1
Dr Rupert Bartsch - Medical University of Vienna, Vienna, Austria
Navigating current treatment options for HER2-positive MBC: Patient journey 1 ( Dr Rupert Bartsch - Medical University of Vienna, Vienna, Austria )
18 Sep 2014
ecancermedicalscience editor's choice for September 2014
Prof Gordon McVie - ecancer and European Institute of Oncology, Milan, Italy
ecancermedicalscience editor's choice for September 2014 ( Prof Gordon McVie - ecancer and European Institute of Oncology, Milan, Italy )
18 Sep 2014
ecancermedicalscience editor's choice for July and August 2014
Prof Gordon McVie - ecancer and European Institute of Oncology, Milan, Italy
ecancermedicalscience editor's choice for July and August 2014 ( Prof Gordon McVie - ecancer and European Institute of Oncology, Milan, Italy )
19 Aug 2014

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation